Provided by Tiger Trade Technology Pte. Ltd.

Rhythm Pharmaceuticals Inc.

95.22
-0.4950-0.52%
Pre-market: 95.940.7250+0.76%07:05 EDT
Volume:737.18K
Turnover:70.75M
Market Cap:6.56B
PE:-30.55
High:97.37
Open:96.67
Low:95.10
Close:95.71
52wk High:122.20
52wk Low:74.50
Shares:68.85M
Float Shares:65.39M
Volume Ratio:0.92
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1172
EPS(LYR):-3.1100
ROE:-117.04%
ROA:-30.96%
PB:63.66
PE(LYR):-30.62

Loading ...

Rhythm Pharmaceuticals Shares up 7.5% Premarket After Q1 Revenue Rises

THOMSON REUTERS
·
May 05

Rhythm Pharmaceuticals Q1 revenue rises 84%

Reuters
·
May 05

Rhythm Q1 FY26 net loss widens to $56.7 million; revenue rises to $60.1 million

Reuters
·
May 05

Stock Track | Rhythm Pharmaceuticals Soars 9.84% in Pre-market on Better-Than-Expected Q1 Results

Stock Track
·
May 05

Rhythm Pharmaceuticals Q1 EPS $(0.83) Beats $(0.84) Estimate, Sales $60.112M Beat $55.776M Estimate

Benzinga Earnings
·
May 05

BRIEF-Rhythm Pharmaceuticals Q1 Net Income USD -55.639 Million Vs. IBES Estimate USD -55.3 Million

Reuters
·
May 05

Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

THOMSON REUTERS
·
May 05

Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data

TIPRANKS
·
May 04

BRIEF-Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society

Reuters
·
May 04

Rhythm presents 2.5-year setmelanotide data in pediatric acquired hypothalamic obesity trial

Reuters
·
May 04

Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society

THOMSON REUTERS
·
May 04

BUZZ-U.S. STOCKS ON THE MOVE-Perella Weinberg Partners, Amkor Technology, Esperion Therapeutics

Reuters
·
May 02

BUZZ-U.S. STOCKS ON THE MOVE-Paramount Skydance, Newell Brands, Rhythm,

Reuters
·
May 01

BUZZ-Rhythm rises after European Commission approves drug for rare form of obesity

Reuters
·
May 01

EU grants Rhythm’s Imcivree approval for acquired hypothalamic obesity treatment

Reuters
·
May 01

Rhythm Pharmaceuticals Announces Imcivree® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients With Acquired Hypothalamic Obesity

THOMSON REUTERS
·
May 01

Rhythm Pharmaceuticals Inc - Commercial Launches of Imcivree in Europe Anticipated in 2027

THOMSON REUTERS
·
May 01

Earning Preview: Rhythm Pharmaceuticals Inc. this quarter’s revenue is expected to increase by 38.35%, and institutional views are bullish

Earnings Agent
·
Apr 28

Analysts Conflicted on These Healthcare Names: Rhythm Pharmaceuticals (RYTM) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Apr 17

Rhythm Pharmaceuticals updates financial calendar with first-quarter results call

Reuters
·
Apr 09